Business Context and Reporting Period
This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. on August 21, 2023. The filing addresses a change in senior management, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Departure: Mr. Jerrold Dotson retired as Chief Financial Officer, effective August 21, 2023.
- Executive Appointment: Ms. Cynthia Anderson, C.P.A., was appointed as the new Chief Financial Officer, effective August 21, 2023.
Management Commentary and Background
Ms. Anderson brings over 15 years of senior leadership experience in the biopharmaceutical industry. Her background includes serving as Chief Accounting Officer for Alnylam Pharmaceuticals, Inc. (2019–2023) and holding senior financial reporting roles at Alexion Pharmaceuticals, Inc. (2011–2019). She previously worked as an Audit Senior Manager at Ernst & Young LLP and in audit roles at PricewaterhouseCoopers LLP. She holds a B.S. in Business Administration and a Master of Science in Accounting and is a certified public accountant.
The Company confirmed there are no arrangements or understandings between Ms. Anderson and any other person regarding her appointment, and she is not a participant in any related party transactions requiring disclosure.
Investor Verification Checklist
- Verify the effective date of the CFO transition (August 21, 2023).
- Review the attached press release (Exhibit 99.1) for additional details on the leadership change.
- Confirm Ms. Anderson's professional credentials and prior employment history as stated in the filing.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.